Atossa Therapeutics, a clinical-stage biopharmaceutical focused on developing (Z)-endoxifen for estrogen receptor positive breast cancer and rare diseases, reported ongoing Phase 2 clinical activities in its latest quarterly filings. While protected by patents until at least 2038 and supported by orphan drug designations, the company continues to operate at a loss with no current revenue streams. Its business hinges on advancing clinical trials successfully, navigating regulatory challenges, securing additional capital, and eventually commercializing its treatment amid competition and systemic healthcare uncertainties.